Details of the Drug Reposition

General Information of This Drug (ID: DM3WP0N)

Drug Name
AL3818   DM3WP0N
Synonyms
Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Alveolar soft part sarcoma DISLKJKZ 2A60-2C35 Phase 3 [1]
Leiomyosarcoma DIS6COXM 2B58 Phase 3 [1]
Synovial sarcoma DISEZJS7 2B5A Phase 3 [1]
------------------------------------------------------------------------------------
5 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Peritoneal cavity cancer DISBT2JS 2C51.Z Phase 1/2 [1]
Ovarian cancer DISZJHAP 2C73 Phase 1/2 [1]
Fallopian tube cancer DISXHWCS 2C74 Phase 1/2 [1]
Endometrial cancer DISW0LMR 2C76 Phase 1/2 [1]
Cervical cancer DISFSHPF 2C77.0 Phase 1/2 [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)